Which has better valuation and earnings, ORKA or SANA?

Oruka Therapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oruka Therapeutics N/A N/A -$105.43M -$1.94 N/A Sana Biotechnology N/A N/A -$244.17M -$0.93 N/A

Is ORKA or SANA more profitable?

Oruka Therapeutics' return on equity of -26.16% beat Sana Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Oruka Therapeutics N/A -26.16% -25.00% Sana Biotechnology N/A -108.01% -40.68%

Does the media refer more to ORKA or SANA?

In the previous week, Sana Biotechnology had 3 more articles in the media than Oruka Therapeutics. MarketBeat recorded 4 mentions for Sana Biotechnology and 1 mentions for Oruka Therapeutics. Oruka Therapeutics' average media sentiment score of 0.58 beat Sana Biotechnology's score of 0.19 indicating that Oruka Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oruka Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sana Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor SANA or BEAM?

In the previous week, Beam Therapeutics had 2 more articles in the media than Sana Biotechnology. MarketBeat recorded 6 mentions for Beam Therapeutics and 4 mentions for Sana Biotechnology. Beam Therapeutics' average media sentiment score of 0.62 beat Sana Biotechnology's score of 0.19 indicating that Beam Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sana Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Beam Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is DNLI or SANA more profitable?

Denali Therapeutics' return on equity of -52.20% beat Sana Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Denali Therapeutics N/A -52.20% -43.86% Sana Biotechnology N/A -108.01% -40.68%

Does the media refer more to DNLI or SANA?

In the previous week, Sana Biotechnology had 2 more articles in the media than Denali Therapeutics. MarketBeat recorded 4 mentions for Sana Biotechnology and 2 mentions for Denali Therapeutics. Sana Biotechnology's average media sentiment score of 0.19 beat Denali Therapeutics' score of 0.13 indicating that Sana Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sana Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, TLX or SANA?

Telix Pharmaceuticals has higher revenue and earnings than Sana Biotechnology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 3.89 -$7.12M N/A N/A Sana Biotechnology N/A N/A -$244.17M -$0.93 N/A

Is TLX or SANA more profitable?

Telix Pharmaceuticals' return on equity of 0.00% beat Sana Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Telix Pharmaceuticals N/A N/A N/A Sana Biotechnology N/A -108.01% -40.68%

Does the media favor TLX or SANA?

In the previous week, Sana Biotechnology had 2 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 4 mentions for Sana Biotechnology and 2 mentions for Telix Pharmaceuticals. Sana Biotechnology's average media sentiment score of 0.19 beat Telix Pharmaceuticals' score of 0.12 indicating that Sana Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sana Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Sana Biotechnology (SANA) Competitors

$2.69 +0.01 (+0.37%)

Closing price 06/8/2026 04:00 PM Eastern

Extended Trading

$2.68 -0.01 (-0.33%)

As of 06/8/2026 07:41 PM Eastern

Compare

SANA vs. ORKA, OGN, BEAM, DNLI, and TLX

Should you buy Sana Biotechnology stock or one of its competitors? MarketBeat compares Sana Biotechnology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sana Biotechnology include Oruka Therapeutics (ORKA), Organon & Co. (OGN), Beam Therapeutics (BEAM), Denali Therapeutics (DNLI), and Telix Pharmaceuticals (TLX). These companies are all part of the "pharmaceutical products" industry.

How does Sana Biotechnology compare to Oruka Therapeutics?

Oruka Therapeutics (NASDAQ:ORKA) and Sana Biotechnology (NASDAQ:SANA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends.

56.4% of Oruka Therapeutics shares are held by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are held by institutional investors. 23.5% of Oruka Therapeutics shares are held by company insiders. Comparatively, 25.4% of Sana Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Oruka Therapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.94	N/A
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A

Oruka Therapeutics' return on equity of -26.16% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-26.16%	-25.00%
Sana Biotechnology	N/A	-108.01%	-40.68%

Oruka Therapeutics has a beta of -0.25, suggesting that its stock price is 125% less volatile than the broader market. Comparatively, Sana Biotechnology has a beta of 2.14, suggesting that its stock price is 114% more volatile than the broader market.

Oruka Therapeutics presently has a consensus target price of $131.30, suggesting a potential upside of 104.96%. Sana Biotechnology has a consensus target price of $9.50, suggesting a potential upside of 253.16%. Given Sana Biotechnology's higher possible upside, analysts clearly believe Sana Biotechnology is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Sana Biotechnology had 3 more articles in the media than Oruka Therapeutics. MarketBeat recorded 4 mentions for Sana Biotechnology and 1 mentions for Oruka Therapeutics. Oruka Therapeutics' average media sentiment score of 0.58 beat Sana Biotechnology's score of 0.19 indicating that Oruka Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oruka Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sana Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Sana Biotechnology beats Oruka Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Sana Biotechnology compare to Organon & Co.?

Sana Biotechnology (NASDAQ:SANA) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk and earnings.

Organon & Co. has a net margin of 3.99% compared to Sana Biotechnology's net margin of 0.00%. Organon & Co.'s return on equity of 99.95% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-108.01%	-40.68%
Organon & Co.	3.99%	99.95%	6.22%

In the previous week, Sana Biotechnology had 4 more articles in the media than Organon & Co.. MarketBeat recorded 4 mentions for Sana Biotechnology and 0 mentions for Organon & Co.. Sana Biotechnology's average media sentiment score of 0.19 beat Organon & Co.'s score of 0.00 indicating that Sana Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Sana Biotechnology	Neutral
Organon & Co.	Neutral

Sana Biotechnology has a beta of 2.14, indicating that its stock price is 114% more volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market.

Organon & Co. has higher revenue and earnings than Sana Biotechnology. Sana Biotechnology is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A
Organon & Co.	$6.22B	0.57	$187M	$0.93	14.39

88.2% of Sana Biotechnology shares are held by institutional investors. Comparatively, 77.4% of Organon & Co. shares are held by institutional investors. 25.4% of Sana Biotechnology shares are held by insiders. Comparatively, 1.6% of Organon & Co. shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Sana Biotechnology currently has a consensus price target of $9.50, indicating a potential upside of 253.16%. Organon & Co. has a consensus price target of $11.40, indicating a potential downside of 14.83%. Given Sana Biotechnology's stronger consensus rating and higher possible upside, research analysts plainly believe Sana Biotechnology is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

Summary

Sana Biotechnology beats Organon & Co. on 8 of the 15 factors compared between the two stocks.

How does Sana Biotechnology compare to Beam Therapeutics?

Sana Biotechnology (NASDAQ:SANA) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

Sana Biotechnology has a beta of 2.14, indicating that its share price is 114% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.25, indicating that its share price is 125% more volatile than the broader market.

In the previous week, Beam Therapeutics had 2 more articles in the media than Sana Biotechnology. MarketBeat recorded 6 mentions for Beam Therapeutics and 4 mentions for Sana Biotechnology. Beam Therapeutics' average media sentiment score of 0.62 beat Sana Biotechnology's score of 0.19 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sana Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Beam Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

88.2% of Sana Biotechnology shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 25.4% of Sana Biotechnology shares are owned by company insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Sana Biotechnology has a net margin of 0.00% compared to Beam Therapeutics' net margin of -39.66%. Beam Therapeutics' return on equity of -29.00% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-108.01%	-40.68%
Beam Therapeutics	-39.66%	-29.00%	-22.61%

Beam Therapeutics has higher revenue and earnings than Sana Biotechnology. Beam Therapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A
Beam Therapeutics	$139.74M	21.92	-$79.99M	-$0.68	N/A

Sana Biotechnology presently has a consensus price target of $9.50, indicating a potential upside of 253.16%. Beam Therapeutics has a consensus price target of $46.83, indicating a potential upside of 57.26%. Given Sana Biotechnology's higher probable upside, analysts clearly believe Sana Biotechnology is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

Beam Therapeutics beats Sana Biotechnology on 12 of the 16 factors compared between the two stocks.

How does Sana Biotechnology compare to Denali Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Sana Biotechnology (NASDAQ:SANA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.

Sana Biotechnology has lower revenue, but higher earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	9.38	-$512.54M	-$2.88	N/A
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A

Denali Therapeutics' return on equity of -52.20% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-52.20%	-43.86%
Sana Biotechnology	N/A	-108.01%	-40.68%

Denali Therapeutics has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market. Comparatively, Sana Biotechnology has a beta of 2.14, indicating that its share price is 114% more volatile than the broader market.

92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are owned by institutional investors. 12.5% of Denali Therapeutics shares are owned by insiders. Comparatively, 25.4% of Sana Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Denali Therapeutics currently has a consensus price target of $34.25, indicating a potential upside of 75.28%. Sana Biotechnology has a consensus price target of $9.50, indicating a potential upside of 253.16%. Given Sana Biotechnology's higher possible upside, analysts plainly believe Sana Biotechnology is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Sana Biotechnology had 2 more articles in the media than Denali Therapeutics. MarketBeat recorded 4 mentions for Sana Biotechnology and 2 mentions for Denali Therapeutics. Sana Biotechnology's average media sentiment score of 0.19 beat Denali Therapeutics' score of 0.13 indicating that Sana Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sana Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Sana Biotechnology beats Denali Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Sana Biotechnology compare to Telix Pharmaceuticals?

Telix Pharmaceuticals (NASDAQ:TLX) and Sana Biotechnology (NASDAQ:SANA) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends.

Telix Pharmaceuticals has a beta of -0.1, suggesting that its stock price is 110% less volatile than the broader market. Comparatively, Sana Biotechnology has a beta of 2.14, suggesting that its stock price is 114% more volatile than the broader market.

Telix Pharmaceuticals' return on equity of 0.00% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Sana Biotechnology	N/A	-108.01%	-40.68%

Telix Pharmaceuticals currently has a consensus price target of $21.13, indicating a potential upside of 129.12%. Sana Biotechnology has a consensus price target of $9.50, indicating a potential upside of 253.16%. Given Sana Biotechnology's higher probable upside, analysts plainly believe Sana Biotechnology is more favorable than Telix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Telix Pharmaceuticals has higher revenue and earnings than Sana Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	3.89	-$7.12M	N/A	N/A
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A

88.2% of Sana Biotechnology shares are held by institutional investors. 25.4% of Sana Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Sana Biotechnology had 2 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 4 mentions for Sana Biotechnology and 2 mentions for Telix Pharmaceuticals. Sana Biotechnology's average media sentiment score of 0.19 beat Telix Pharmaceuticals' score of 0.12 indicating that Sana Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sana Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Sana Biotechnology beats Telix Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Get Sana Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SANA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SANA vs. The Competition

Export

Metric	Sana Biotechnology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$745.82M	$3.34B	$6.49B	$11.99B
Dividend Yield	N/A	2.30%	2.67%	5.57%
P/E Ratio	-2.89	18.61	23.68	23.74
Price / Sales	N/A	298.01	507.33	108.39
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	4.48	8.04	10.28	6.78
Net Income	-$244.17M	$23.89M	$3.57B	$337.51M
7 Day Performance	-16.98%	-3.28%	0.28%	-2.34%
1 Month Performance	-23.36%	2.78%	3.27%	1.88%
1 Year Performance	-4.95%	36.03%	22.22%	25.55%

Sana Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SANA Sana Biotechnology	3.4484 of 5 stars	$2.69 +0.4%	$9.50 +253.2%	-5.3%	$745.82M	N/A	N/A	380	Analyst Downgrade Gap Up
ORKA Oruka Therapeutics	3.5105 of 5 stars	$55.01 -6.0%	$120.80 +119.6%	+409.2%	$3.53B	N/A	N/A	N/A	Gap Up
OGN Organon & Co.	2.0685 of 5 stars	$13.37 +0.2%	$11.40 -14.7%	+40.0%	$3.50B	$6.22B	14.37	10,000	Positive News
BEAM Beam Therapeutics	2.5151 of 5 stars	$31.14 -5.4%	$46.83 +50.4%	+60.3%	$3.39B	$139.74M	N/A	510	Gap Up
DNLI Denali Therapeutics	3.2705 of 5 stars	$20.41 -3.0%	$34.25 +67.8%	+32.9%	$3.34B	N/A	N/A	430

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SANA) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sana Biotechnology (SANA) Competitors

SANA vs. ORKA, OGN, BEAM, DNLI, and TLX

How does Sana Biotechnology compare to Oruka Therapeutics?

Summary

How does Sana Biotechnology compare to Organon & Co.?

Summary

How does Sana Biotechnology compare to Beam Therapeutics?

Summary

How does Sana Biotechnology compare to Denali Therapeutics?

Summary

How does Sana Biotechnology compare to Telix Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SANA vs. The Competition

Sana Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sana Biotechnology (SANA) Competitors

SANA vs. ORKA, OGN, BEAM, DNLI, and TLX

How does Sana Biotechnology compare to Oruka Therapeutics?

Do institutionals and insiders have more ownership in ORKA or SANA?

Which has better valuation and earnings, ORKA or SANA?

Is ORKA or SANA more profitable?

Which has more risk and volatility, ORKA or SANA?

Do analysts rate ORKA or SANA?

Does the media refer more to ORKA or SANA?

Summary

How does Sana Biotechnology compare to Organon & Co.?

Is SANA or OGN more profitable?

Does the media prefer SANA or OGN?

Which has more volatility & risk, SANA or OGN?

Which has better earnings and valuation, SANA or OGN?

Do insiders & institutionals hold more shares of SANA or OGN?

Do analysts rate SANA or OGN?

Summary

How does Sana Biotechnology compare to Beam Therapeutics?

Which has more volatility and risk, SANA or BEAM?

Does the media favor SANA or BEAM?

Do institutionals and insiders have more ownership in SANA or BEAM?

Is SANA or BEAM more profitable?

Which has stronger earnings and valuation, SANA or BEAM?

Do analysts rate SANA or BEAM?

Summary

How does Sana Biotechnology compare to Denali Therapeutics?

Which has better earnings and valuation, DNLI or SANA?

Is DNLI or SANA more profitable?

Which has more risk & volatility, DNLI or SANA?

Do institutionals & insiders have more ownership in DNLI or SANA?

Do analysts recommend DNLI or SANA?

Does the media refer more to DNLI or SANA?

Summary

How does Sana Biotechnology compare to Telix Pharmaceuticals?

Which has more risk & volatility, TLX or SANA?

Is TLX or SANA more profitable?

Do analysts prefer TLX or SANA?

Which has better valuation & earnings, TLX or SANA?

Do institutionals and insiders have more ownership in TLX or SANA?

Does the media favor TLX or SANA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SANA vs. The Competition

Sana Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools